Product Update

Deltex Medical Group PLC
24 June 2005

24 June 2005



             Deltex Medical Group plc ('Deltex Medical' / 'Company')

Leading doctors group puts CardioQTM at the heart of improving surgical outcomes
                                 in the UK NHS


Deltex Medical today announces the publication by an independent group of the
UK's leading doctors of a pamphlet entitled 'Modernising Care for Patients
Undergoing Major Surgery: Improving Patient Outcomes and Increasing Clinical
Efficiency'.


The pamphlet notes that at least 20,000 NHS patients a year die after surgery
and that many of these die due to out-dated standards of care before, during and
after surgery.  Patients having moderate and major surgery in the NHS are three
or four times more likely to die than equivalent patients in other developed
countries.


The doctors, who include some of the UK's leading surgeons, anaesthetists and
intensive care specialists, advocate a three-step evidence-based solution to the
problems: firstly the implementation of fluid optimisation of patients during
their surgery, secondly the provision of the appropriate levels of care in the
crucial post-operative period, and thirdly the introduction of rigorous
pre-operative fitness testing to ensure that care plans are tailored to the
individual patient's need.


The first step, fluid optimisation (ensuring that the patient has sufficient
circulating blood volume), can be implemented easily and cheaply without any
changes to current care pathways or staffing levels; it means patients leave
operating theatres in better condition, suffering fewer post-operative
complications and therefore spend less time in critical care and on the wards.
The beds and staff freed up can then be redeployed to provide intermediate
levels of post-operative care.  Deltex Medical's CardioQ is the only technology
available today which offers surgeons a proven solution in operating theatres to
the near universal problem of hypovolaemia (a shortage of circulating blood
volume) and the post-operative complications it causes.


Deltex Medical's Chief Executive, Andy Hill commented:


'Fifteen thousand or more patients are dying unnecessarily in the NHS each year
after surgery - fifteen times more than die from hospital acquired infections
like MRSA.  Many tens of thousands more patients suffer avoidable complications
and unnecessarily long and difficult recoveries following their surgery.  Fluid
optimisation of moderate and major risk surgical patients alone could more than
halve the numbers of patients dying.  We know that implementing intra-operative
fluid optimisation using the Company's CardioQ would save the NHS many hundreds
of millions of pounds every year, thereby freeing up the resources to allow the
NHS to once more provide world class care to about one million higher risk
patients every year.'


For further information, please contact:-

Deltex Medical Group plc                                           01243 774 837
Nigel Keen, Chairman              [e-mail]
Andy Hill, Chief Executive        [e-mail]
Ewan Phillips, Finance Director   [e-mail]

Financial Dynamics                                                 0207 831 3113
David Yates                           [e-mail]
Lucy Briggs                           [e-mail]


A conference call for analysts will be held at 9.30am UK time today.  Please
call Lucy Briggs on 020 7269 7223 for details.


Notes for Editors


Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQ, to optimise the amount
of circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.


The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.


There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-


  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works

  • proved that the CardioQ works in a wide range of surgical procedures

  • demonstrated that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.






                      This information is provided by RNS
            The company news service from the London Stock Exchange